Skip to main content
JEONJINBIO CO., LTD. logo

JEONJINBIO CO., LTD. — Investor Relations & Filings

Ticker · 110020 ISIN · KR7110020005 KO Manufacturing
Open in API
Filings indexed 371 across all filing types
Latest filing 2023-03-21 Annual Report
Country KR South Korea
Listing KO 110020

About JEONJINBIO CO., LTD.

http://jjbious.com/01

JEONJINBIO CO., LTD. is a biotechnology company specializing in the research, development, and production of products for pest control and the mitigation of damage from nuisance animals. The company's core offerings consist of natural bio-pesticides and repellents formulated from natural materials as alternatives to conventional chemical products. Its product line includes specialized solutions for repelling birds, boars, and other animals. The company emphasizes innovation and safety, supported by its dedicated research and development center and various product certifications, including USA EPA approval for its bird repellent.

Recent filings

Filing Released Lang Actions
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the 19th fiscal year (2022) of Jeonjin Bio Pharm Co., Ltd. It contains comprehensive financial statements, management discussion and analysis, governance information, and auditor's opinions. This document is the standard annual filing required by the Financial Supervisory Service (FSS) in South Korea, which corresponds to the 10-K filing type in the provided schema. FY 2022
2023-03-21 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a regulatory filing from the Korea Exchange (KRX) system titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data, and capital impairment status for the fiscal year. While it contains audit-related information, it is a standard regulatory disclosure announcement (DART/KIND filing) rather than the full, multi-page audit report document itself. Given the structure and the nature of the disclosure, it fits the 'Audit Report / Information' category as it provides the specific audit results and financial summary required by regulators. FY 2022
2023-03-21 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing from the Korea Exchange (KRX) system regarding the 'Acquisition of Convertible Bonds before Maturity' (전환사채 발행후 만기전 사채 취득). It details specific financial data about the bond, the acquisition date, the amount, and the reason (early redemption request by the bondholder). This falls under capital structure and financing updates, specifically related to debt management. Since it is a specific regulatory disclosure regarding a change in the company's debt/capital structure, it is classified as a Capital/Financing Update (CAP).
2023-03-20 Korean
주식등의대량보유상황보고서(약식)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed in South Korea. It details changes in share ownership by Susung Asset Management in the company Jeonjin Bio Pharm. This type of filing is specifically used to notify the market when an entity's shareholding crosses certain thresholds (typically 5%), which corresponds to the 'Major Shareholding Notification' category.
2023-03-17 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Jeonjin BioPharm. It contains the meeting agenda, financial statements (balance sheet, income statement, etc.) for the 19th fiscal year, and management information regarding board activities. While it contains financial data, it is primarily a proxy statement/notice for shareholders to attend the AGM and vote on agenda items. In the context of the provided categories, this fits best as a Proxy Solicitation & Information Statement (PSI) as it provides the necessary information for shareholders to exercise their voting rights at the upcoming meeting.
2023-03-14 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a 'General Meeting of Shareholders' (주주총회소집결의) issued by Jeonjin BioPharm. It outlines the date, location, agenda items (such as financial statement approval, director/auditor compensation, and business purpose changes), and details regarding the auditor appointment. This document serves as the official proxy solicitation and information statement provided to shareholders to inform them of the upcoming meeting and the matters to be voted upon. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2023-03-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.